news
System secures $20M to scale clinician-led peptide protocols
System, a brand focusing on peptides, just raised $20 million to grow its business, aiming to offer better quality, transparency, and clinical oversight in a category that's often a bit murky. They're betting on clinician-led protocols to differentiate them in a booming market.
System, a brand focusing on peptides, just raised $20 million to grow its business, aiming to offer better quality, transparency, and clinical oversight in a category that's often a bit murky. They're betting on clinician-led protocols to differentiate them in a booming market.
The architecture take
I just saw a friend try a peptide protocol from an online clinic; it felt like a wild west. This $20 million raise for System is all about bringing some order to that chaos, making peptides feel less like a dark alley deal and more like actual medicine. They're pushing for clinician-led protocols, which means a doctor or nurse practitioner is guiding the specific peptide—think BPC-157 for gut repair or KPV for inflammation—and monitoring your body's response. This isn't just about selling bottles; it's about controlling the supply chain, ensuring what's in the vial is actually what it says it is, and then having someone qualified tell you how to use it. When you hear about "quality control" and "transparency" in peptides, it's because the current market can be full of sketch. Expect to see more brands chasing this clinical-grade, verified route as consumers get smarter about what they're putting into their bodies, especially when it costs real money. It's about reducing the physiological load of guessing.